blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3679936

EP3679936 - USE OF VERBASCOSIDE IN PREPARATION OF DRUG FOR PREVENTING OR TREATING GLOMERULAR PODOCYTE INJURED RENAL DISEASE [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  28.08.2020
Database last updated on 24.03.2026
FormerRequest for examination was made
Status updated on  12.06.2020
FormerThe international publication has been made
Status updated on  08.03.2019
Most recent event   Tooltip14.02.2026New entry: Despatch of examination report + time limit 
Applicant(s)For all designated states
Sichuan Medco Pharmaceutical Stock Co., Ltd.
East Jinhe Road
Shifang
Deyang, Sichuan 618400 / CN
[2020/29]
Inventor(s)01 / ZHANG, Xiaoqi
SICHUAN MEDCO PHARMACEUTICAL STOCK CO., LTD.
East Jinhe Road
Shifang Deyang
Sichuan 618400 / CN
 [2020/41]
Former [2020/29]01 / ZHANG, Xiaoqi
East Jinhe Road
Shifang
Deyang Sichuan 618400 / CN
Representative(s)Loyer & Abello
9, rue Anatole de la Forge
75017 Paris / FR
[2020/29]
Application number, filing date17923035.413.10.2017
[2020/29]
WO2017CN106171
Priority number, dateCN20171078392804.09.2017         Original published format: CN201710783928
[2020/29]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019041467
Date:07.03.2019
Language:ZH
[2019/10]
Type: A1 Application with search report 
No.:EP3679936
Date:15.07.2020
Language:EN
[2020/29]
Search report(s)International search report - published on:CN07.03.2019
(Supplementary) European search report - dispatched on:EP11.08.2020
ClassificationIPC:A61K31/7034, A61P13/12, A61P3/10, A61K31/7028
[2020/37]
CPC:
A61K31/7028 (EP); A61K31/7034 (EP,CN,US); A61P13/12 (EP,US);
A61K47/10 (US); A61K47/32 (US); A61K47/38 (US)
Former IPC [2020/29]A61K31/7034, A61P13/12, A61P3/10
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/29]
TitleGerman:VERWENDUNG VON VERBASCOSID BEI DER HERSTELLUNG EINES ARZNEIMITTELS ZUR VORBEUGUNG ODER BEHANDLUNG VON GLOMERULÄRER NIERENERKRANKUNG MIT PODOZYTENLÄSIONEN[2020/29]
English:USE OF VERBASCOSIDE IN PREPARATION OF DRUG FOR PREVENTING OR TREATING GLOMERULAR PODOCYTE INJURED RENAL DISEASE[2020/29]
French:UTILISATION DU VERBASCOSIDE DANS LA PRÉPARATION D'UN MÉDICAMENT POUR PRÉVENIR OU TRAITER LES MALADIES RÉNALES LIÉES À UNE LÉSION DES PODOCYTES GLOMÉRULAIRES[2020/29]
Entry into regional phase01.04.2020Translation filed 
03.04.2020National basic fee paid 
01.04.2020Search fee paid 
01.04.2020Designation fee(s) paid 
03.04.2020Examination fee paid 
Examination procedure01.04.2020Amendment by applicant (claims and/or description)
03.04.2020Examination requested  [2020/29]
27.08.2020Despatch of a communication from the examining division (Time limit: M04)
05.01.2021Reply to a communication from the examining division
14.11.2022Despatch of a communication from the examining division (Time limit: M04)
22.03.2023Reply to a communication from the examining division
19.06.2023Despatch of a communication from the examining division (Time limit: M04)
27.10.2023Reply to a communication from the examining division
25.04.2024Despatch of a communication from the examining division (Time limit: M04)
23.08.2024Reply to a communication from the examining division
30.04.2025Despatch of a communication from the examining division (Time limit: M04)
28.08.2025Reply to a communication from the examining division
13.02.2026Despatch of a communication from the examining division (Time limit: M04)
Fees paidRenewal fee
03.04.2020Renewal fee patent year 03
22.10.2020Renewal fee patent year 04
19.10.2021Renewal fee patent year 05
31.10.2022Renewal fee patent year 06
16.11.2023Renewal fee patent year 07
29.10.2024Renewal fee patent year 08
27.10.2025Renewal fee patent year 09
Penalty fee
Additional fee for renewal fee
31.10.202307   M06   Fee paid on   16.11.2023
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[I] US2011144040  (WELLS SHAWN et al.) [I] 3-12 * paragraph [0021] - paragraph [0023] *
 [XI]   ANONYMOUS: "Abstract 132: Glomerular Podocyte Damage is Mitigated by Normal HDL and ApoA1 | Arteriosclerosis, Thrombosis, and Vascular Biology", 25 August 2017 (2017-08-25), XP055717924, Retrieved from the Internet [retrieved on 20200724] [X] 1 * the whole document *[I] 2
 [XI]   H QIU ET AL: "General acteoside of rehmanniae leaves in the treatment of primary chronic glomerulonephritis: A randomized controlled trial", AFRICAN JOURNAL OF TRADITIONAL, COMPLEMENTARY AND ALTERNATIVE MEDICINES, vol. 10, no. 4, 18 June 2013 (2013-06-18), XP055717862, DOI: 10.4314/ajtcam.v10i4.18 [X] 1 * page 113 - page 114 *[I] 2-12

DOI:   http://dx.doi.org/10.4314/ajtcam.v10i4.18
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.